Abstract Views
PDF Download
Clinical Chemistry

Inhibitory potentials of ivermectin, nafamostat, and camostat on spike protein and some nonstructural proteins of SARS-CoV-2: Virtual screening approach

, , , , ,
Pages 33-42


The search for potent oral drugs either through synthetic routes or by drug repurposing for combating the dreaded covid-19 virus is still ongoing. The coronavirus spike glycoprotein and several other non-structural proteins play crucial roles in the replication and transmission of this virus. Recent research have identified ivermectin, nafamostat, and camostat as promising drug inhibitors of SARS-CoV-2 target proteins. The broad-spectrum inhibitory action of ivermectin, nafamostat, and camostat on the spike glycoprotein and some non-structural proteins of this virus was studied in silico. The spike glycoprotein, nsp3, nsp5, nsp9, nsp10, nsp13, and nsp16 were selected for this study and were downloaded from the protein data bank. Flexible docking procedure implemented in Auto Dock Vina module was deployed for the docking procedure of the drugs with the protein receptors. Although ivermectin had the best inhibitory action on the viral spike protein and nsp10, nafamostat was identified as the compound with the best broad-spectrum activity on this virus, having the highest binding affinity values of – 9.4kcal/mol, – 7.9 Kcal/mol, – 6.1 Kcal/mol, – 8.0 Kcal/mol, and – 8.7 Kcal/mol for nsp3, nsp5, nsp9, nsp13, and nsp16 respectively. This drug, in combination with ivermectin could therefore be explored further as potential compounds that could be modified to curb the menace of the covid-19 pandemic.

There is no Figure or data content available for this article


  • Shi Y., Y. Wang, C. Shao, J. Huang, J. Gan, X. Huang, E. Bucci, M. Piacentini, G. Ippolito, G. Melino, COVID-19 infection: the perspectives on immune responses, Cell Death Differ. (2020), https://doi.org/10.1038/s41418-020-0530-3
  • Faheem, Kumar BK, Sekhar KVGC, Kunjiappan S, Jamalis J, Balaña-Fouce R, Tekwani BL, Sankaranarayanan M. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorg Chem104:104269. https://doi.org/10.1016/j.bioorg.2020.104269
  • Yan R., ZhangY., Li Y., Xia, L.,Guo Y., Zhou Q. (2020). Structural basis for the recognition of SARS Cov-2 by full-lenght human ACE2. Science 367, 1444-1448.
  • Watanabe Y., Allen JD.,Wrapp O., Mclellan JS., Crispin M. (2020). Site-specific glycan analysis of the SARS-Cov-2 spike.Science. 2020.369;330-333.
  • Ma-Lauer Y, Carbajo -Lozoya J, Hein MY, Muller MA, Deng W, Lei J, Meyer B, Kusov Y, Von-Brun B, Bairad DR, Hunten S, Drosten C, Hermeking H, Leonhardt H, Mann M, Hilgenfield R (2016). Nsp3 down-regulates SARS corona virus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc. Natl. Acad. Sci. 113:E55192-E5201.
  • Wolff G., Melia CE., Snijder EJ., Barcena R. (2020).Double membrane vessicles as platforms for viral relication.Trends in Microbiology, https://doi.org/10.1016/j.tim.2020.05.009
  • Macchiagodena M., Pagliai M., Procacci P. (2020). Identification and potential binders of the main protease 3CL(pro) of the covid-19 via structure- based ligand design and molecular modeling. ChemPhysLett. 750:137489.
  • Durdagi S., Aksoydan B., Dogan B., Sahin K., Shahraki A. (2020). Sreening of clinically approved and investigation drugs as potential inhibitors of COVID-19 main protease: A virtual drug repurposing study. DOI:10.26434/chemrxiv.12032712.v1.
  • Zeng Z., Deng F., Shi K., Ye G., Wang G., Fang L. (2018). Dimerization of coronavirus nsp9 with diverse modes enhances its nucleic acid binding affinity. J Virol.92, e00692-18.
  • Ma T., Wu L., Shaw N., Gao Y., Wang J., Sun Y. (2015). Structural basis and functional analysis of the SARS-corona virus nsp14-nsp10 complex.ProcNatlAcad Sci, 112:9436-9441.
  • Rosas-Lemus M, G. Minasov, L. Shuvalova, N. L. Inniss, O. Kiryukhina, J. Brunzelle,nK. J. F. Satchell, High-resolution structures of the SARS-CoV-2 2?-O-methyltransferase reveal strategies for structure-based inhibitor design. Sci. Signal. 13, eabe1202 (2020).
  • Hao W., Wojdyla J.A., Zhao R., Han R., Das R., Zlatev I. (2017). Crystal structure of middle East respiratory syndrome coronavirus helicase. PLoSPathog 13, e1006474.
  • 13.Jia Z., Yan L., Ren Z., Wu L., Wang J., Guo J. (2019). Delicate structural coordination of the severe acute respiratory syndrome coronavirus nsp13 upon ATP hydrolysis.Nucleic acids Research, 47, 6538-6550.
  • Ramanathan A., Robb GB., Chan S.H. (2016). mRNA capping: Biological functions and applications. Nucleic acid Research. 44:7511-7526
  • Sawicki S.G., Sawicki D.L., Younker D., Meyer Y., Thiel V., Stokes H., Sidell S.G. (2005). Functional and genetic analysis of coronavirus replicase-transcriptase proteins.PLoSPathog. 1:e39.
  • Decroly E., Imbert I., Coutard B., Bouvet M., Selisko B., Alvarez K., Gorbalenya A.E., Snijder E.J., Canard B (2008). Corona virus nonstructural protein 16 is a Cap-0 binding enzyme possessing (Nucleoside-2'O)-methyltransferase. Activity J. Virol. 82: 8071-8084.
  • Snijder E.J., Decroly E.J., Zierbuhr J. (2016). The non structural proteins directing corona virus RNA synthesis and processing. Adv. Virus. Res. 96: 59-126.
  • Marcolino VA, Pimentel TC, Barão CE (2020). What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. European journal of pharmacology, 887, 173467.https://doi.org/10.1016/j.ejphar.2020.173467
  • Umar HI, Josiah SS, Saliu TP, Jimoh TO, Ajayi A, Danjuma JB.In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from select African plants. J TaibahUniv Medical Sci 2021; https://doi.org/10.1016/j.jtumed.2020.12.005
  • Duru CE, I.A. Duru, and A.E. Adegboyega (2021a). In Silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets. Bulletin of the National Research Centre, 45:57. https://doi.org/10.1186/s42269-021-00517-x
  • Duru C.E., Haruna Umar H.I., Duru I.A., Enenbeaku U.E., Ngozi-Olehi L.C., Enyoh C.E. (2021b). Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective. Environmental Analysis Health and Toxicology, 36(2), e2021010. https://doi.org/10.5620/eaht.2021010
  • Stroganov OV, Novikov FN, Zeifman AA, Stroylov VS, Chilov GG. TSAR, a new graph-theoretical approach to computational modeling of protein side-chain flexibility: modeling of ionization properties of proteins. Proteins, 2011 79(9):2693-2710. https://doi.org/10.1002/prot.23099
  • Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Computational Chemistry 2010; 31: 455–461.
  • Gao X, Qin B, Chen P, Zhu K, Hou P,Wojdyla JA, Wang M, Cui S.Crystal structure of SARS-CoV-2 papain-like protease. Acta PharmaceuticaSinica B 2021;11(1):237e245. https://doi.org/10.1016/j.apsb.2020.08.014
  • Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y (2020) Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:1–24. http://dx.doi.org/10.1038/s41586-020-2223-y
  • Littler DR, Gully BS, Colson RN,Rossjohn J. Crystal structure of the SARS-CoV-2 non-structural protein 9, Nsp9. iScience 2020; 23:101258. https://doi.org/10.1016/j.isci.2020.101258
  • Rosas-Lemus M., Minasov G., Shuvalova L., Inniss N., Kiryukhina O., Wiersum G. (2020a). The crystal structure of nsp10-nsp16 heterodimer from SARS-Cov-2 in complex with S-adenosylmethionine. https://doi.org/10.1101/2020.04.17.047498
  • Chen J, Malone B, Llewellyn E, Grasso M, Shelton PMM, Olinares PDB, Maruthi K, Eng ET, Vatandaslar H, Chait BT, Kapoor TM, Darst SA, Campbell EA. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. Cell, 182(6):1560-1573. https://doi.org/10.1016/j.cell.2020.07.033
  • Krafcikova P, Silhan J, Nencka R, Boura E. Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to Sinefungin. Nature Communications 2020; 11:1-7. https://doi.org/10.1038/s41467-020-17495-9
  • Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K, Wang Q, Zhou H, Yan J, Qi J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell, 2020; 181, 894–904. https://doi.org/10.1016/j.cell.2020.03.045
  • Breining P, Frølund AL, Højen JF, et al. Camostatmesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. Basic Clin. PharmacolToxicol. 2021, 128:204–212.
  • Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2):271-280.
  • Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue J, Matsuda Z (2016). Identification of nafamostat as a potent inhibitor of Middle Eastrespiratory syndrome coronavirus S Protein-mediated membranefusion using the split-protein-based cell-cell fusion assay. Antimicrobial Agents and Chemotherapy, 60(11):6532-6537.
  • Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F, Giráldez M, Laso E, Gabaldón-Figueira JC, Dobaño C, Moncunill G, Yuste JR, Del Pozo JL, Rabinovich NR, Schöning V, Hammann F, Reina G, Sadaba B, Fernández-Alonso M. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, 2021, 32:100720.http://dx.doi.org/10.1016/j.eclinm.2020.100720
  • Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020, 178:104787.
  • Duru CE, I.A. Duru, B.A.A. García, and U.E. Enenebeaku (2021c). Computational modeling of the activity of metronidazole against EhG?1 of Entamoeba histolytica enhanced by its copper and zinc complexes. Chemistry Africa. https://doi.org/10.1007/s42250-021-00245-9
There is no Supplemental content for this article.

How to Cite This

Umar, H. I., Duru, I. A., Enenebeaku, U. E., Olehi, L. C. N., Enyoh, C. E., & Duru, C. E. (2022). Inhibitory potentials of ivermectin, nafamostat, and camostat on spike protein and some nonstructural proteins of SARS-CoV-2: Virtual screening approach . Jurnal Teknologi Laboratorium, 11(1), 33–42. https://doi.org/10.29238/teknolabjournal.v11i1.344

Article Metrics

Download Statistics


Download data is not yet available.


Metrics Loading ...

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability